Department of Colorectal Surgical Oncology, The Tumor Hospital of Harbin Medical University, Harbin 150001, China.
Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
Aging (Albany NY). 2022 Aug 26;14(16):6756-6779. doi: 10.18632/aging.204250.
The increasing number of young colorectal cancer (CRC) survivors has led to ongoing concerns about the risk of secondary primary malignancies (SPMs). Here, we intended to comprehensively explore the pooled standardized incidence rates (SIRs) for total and site-specific SPMs in CRC survivors with different restriction to lag period.
Pubmed, Embase, Cochrane Library, and Web of science databases were searched to identify any studies reporting the SIRs of SPM following CRC until August 2021. Total and site-specific SIRs with different restriction to lag period were pooled using fixed/random effect models.
A total of 42 full-text publications with more than 1, 524, 236 CRC survivors and 166, 210 SPM patients were included in the meta-analysis. Pooled data showed an increased SIRs for all SPMs in CRC survivors with different restriction to lag period (no restriction to lag period, SIR = 1.15, 95% CI = [1.08-1.23]; 1-year lag, 1.16 [1.10-1.23]; 5-year lag, 1.18 [1.09-1.28]; 10-year lag, 1.24 [1.11-1.39]). The conclusions were consistent for neoplasms of colorectum, corpus uteri, and small intestine with different restriction to lag period. However, limited evidence was presented for associations between CRC survivors and SPM for prostate, breast (female), ovarian, stomach, urinary bladder, kidney, thyroid, bone and soft tissue.
CRC survivors are associated with an increased risk of SPMs, especially neoplasms of colorectum, corpus uteri, and small intestine. Further studies should explore the risks for these neoplasms in CRC survivors, thus providing the reference for future follow-up care.
越来越多的年轻结直肠癌(CRC)幸存者导致人们持续关注继发性原发性恶性肿瘤(SPM)的风险。在这里,我们旨在全面探讨不同潜伏期限制下 CRC 幸存者的总 SPM 和特定部位 SPM 的汇总标准化发病比(SIR)。
检索 Pubmed、Embase、Cochrane 图书馆和 Web of science 数据库,以确定截至 2021 年 8 月报告 CRC 后 SPM 的 SIR 的任何研究。使用固定/随机效应模型汇总不同潜伏期限制的总 SPM 和特定部位 SIR。
共有 42 篇全文文献纳入了荟萃分析,其中包括超过 1524236 例 CRC 幸存者和 166210 例 SPM 患者。汇总数据显示,不同潜伏期限制下 CRC 幸存者的所有 SPM 的 SIR 均升高(无潜伏期限制,SIR=1.15,95%CI=[1.08-1.23];1 年潜伏期,1.16[1.10-1.23];5 年潜伏期,1.18[1.09-1.28];10 年潜伏期,1.24[1.11-1.39])。对于不同潜伏期限制的结直肠、子宫体和小肠肿瘤,结论是一致的。然而,对于前列腺、女性乳房、卵巢、胃、膀胱、肾、甲状腺、骨和软组织,CRC 幸存者与 SPM 之间的关联证据有限。
CRC 幸存者与 SPM 的风险增加相关,尤其是结直肠、子宫体和小肠肿瘤。应进一步研究 CRC 幸存者中这些肿瘤的风险,从而为未来的随访护理提供参考。